Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGE-547 for super-refractory status epilepticus
2015-002142-31Phase 3Completed
- Sponsor
- Sage Therapeutics
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in status epilepticus (SE) comparing SAGE-547 infusion with Placebo infusion (2 arms). Primary endpoint: Primary response. Started Aug 2015; status: completed.
02
Drugs
brexanolone
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on 2015-002142-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002142-31.